Aspire Biopharma regained Nasdaq compliance and avoids delisting after meeting equity requirements.

Aspire Biopharma (ASBP) has regained full compliance with Nasdaq listing rules, meeting the $2.5 million stockholders' equity requirement after previously satisfying the $1.00 minimum bid price. The company’s stock will remain listed on Nasdaq, though it will be under a one-year "Panel Monitor" until February 18, 2027. During this period, failure to maintain the equity threshold would trigger a delisting hearing. Aspire develops sublingual drug delivery technology aimed at rapid, precise medication delivery, bypassing the digestive system, with potential use across various therapeutics and supplements. Forward-looking statements in the release involve risks and should not be viewed as guarantees.